| A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis | Active, not recruiting | Colitis, Ulcerative|Inflammatory Bowel Diseases | Drug: Placebo IV|Drug: Placebo SC|Drug: Ustekinumab IV|Drug: Ustekinumab SC | Janssen Research & Development, LLC | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator) | July 10, 2015 | https://ClinicalTrials.gov/show/NCT02407236 |
| Efficacy and Safety Study of Apremilast to Treat Active Ulcerative Colitis | Active, not recruiting | Ulcerative Colitis | Drug: Apremilast|Drug: Placebo | Celgene | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment | December 10, 2014 | https://ClinicalTrials.gov/show/NCT02289417 |
| BI 695501 Versus Humira in Patients With Active Crohn's Disease: a Trial Comparing Efficacy, Endoscopic Improvement, Safety, and Immunogenicity | Active, not recruiting | Crohn Disease | Drug: BI 695501|Drug: HUMIRA | Boehringer Ingelheim | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment | September 28, 2016 | https://ClinicalTrials.gov/show/NCT02871635 |
| Efficacy and Safety of Vedolizumab Subcutaneous (SC) as Maintenance Therapy in Crohn's Disease | Active, not recruiting | Crohn's Disease | Drug: Vedolizumab SC 108 mg|Drug: Placebo|Drug: Vedolizumab IV 300 mg | Takeda | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment | January 4, 2016 | https://ClinicalTrials.gov/show/NCT02611817 |
| Efficacy and Safety Trial of RPC1063 for Moderate to Severe Crohn's Disease | Active, not recruiting | Crohn's Disease | Drug: RPC1063 | Celgene | Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | October 9, 2015 | https://ClinicalTrials.gov/show/NCT02531113 |
| Study to Evaluate Efficacy and Safety of Two Drug Regimens in Subjects With Moderate to Severe Crohn's Disease | Active, not recruiting | Crohn's Disease | Drug: Adalimumab | AbbVie | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment | April 9, 2014 | https://ClinicalTrials.gov/show/NCT02065570 |
| Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis | Active, not recruiting | Ulcerative Colitis | Drug: Etrasimod|Drug: Placebo | Arena Pharmaceuticals | Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment | November 2015 | https://ClinicalTrials.gov/show/NCT02536404 |
| An Efficacy and Safety Study of Vedolizumab Intravenous (IV) Compared to Adalimumab Subcutaneous (SC) in Participants With Ulcerative Colitis | Active, not recruiting | Colitis, Ulcerative | Drug: Vedolizumab|Drug: Adalimumab placebo|Drug: Adalimumab|Drug: Vedolizumab placebo | Takeda | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment | July 15, 2015 | https://ClinicalTrials.gov/show/NCT02497469 |
| Efficacy and Safety Study of RPC1063 in Ulcerative Colitis | Active, not recruiting | Ulcerative Colitis | Drug: RPC1063|Drug: placebo | Celgene | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment | December 12, 2012 | https://ClinicalTrials.gov/show/NCT01647516 |
| Long-Term Study Of CP-690,550 In Subjects With Ulcerative Colitis | Active, not recruiting | Ulcerative Colitis | Drug: CP-690,550 | Pfizer | Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | October 1, 2012 | https://ClinicalTrials.gov/show/NCT01470612 |
| Study to Evaluate the Safety and Efficacy of Two Drug Regimens in Subjects With Moderate to Severe Ulcerative Colitis | Active, not recruiting | Ulcerative Colitis (UC) | Drug: Adalimumab|Other: Placebo | AbbVie | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment | March 28, 2014 | https://ClinicalTrials.gov/show/NCT02065622 |
| Extended Access Program of Vedolizumab IV in Ulcerative Colitis and Crohn's Disease | Active, not recruiting | Colitis, Ulcerative|Crohn Disease | Drug: Vedolizumab | Takeda | Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | August 1, 2016 | https://ClinicalTrials.gov/show/NCT02743806 |
| A Study of YM060 in Diarrhea-predominant Irritable Bowel Syndrome (d-IBS) | Completed | Irritable Bowel Syndrome | Drug: YM060 | Astellas Pharma Inc|Astellas Pharma Europe B.V. | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment | March 2005 | https://ClinicalTrials.gov/show/NCT00189813 |
| Ibodutant for Relief of Irritable Bowel Syndrome (IRIS) | Completed | Irritable Bowel Syndrome | Drug: Ibodutant|Drug: Placebo | Menarini Group | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment | July 2008 | https://ClinicalTrials.gov/show/NCT00761007 |
| A Double Blind Study for the Treatment of Acute Ulcerative Colitis | Completed | Ulcerative Colitis | Drug: Mesalamine | Warner Chilcott | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment | June 2006 | https://ClinicalTrials.gov/show/NCT00350415 |
| A Study of TRK-170 for the Treatment of Crohn's Disease | Completed | Crohn's Disease | Drug: TRK-170|Drug: Placebo | Toray Industries, Inc | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment | April 2011 | https://ClinicalTrials.gov/show/NCT01345799 |
| A Study Of Oral CP-690,550 As A Maintenance Therapy For Ulcerative Colitis | Completed | Ulcerative Colitis | Drug: Placebo|Drug: CP690,550|Drug: CP-690,550 | Pfizer | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment | July 20, 2012 | https://ClinicalTrials.gov/show/NCT01458574 |
| A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease | Completed | Crohn's Disease | Drug: Placebo|Drug: CP-690,550 | Pfizer | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment | October 2011 | https://ClinicalTrials.gov/show/NCT01393626 |
| A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease | Completed | Crohn Disease | Biological: Cimzia | UCB BIOSCIENCES GmbH|PPD|UCB Pharma | Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | May 2008 | https://ClinicalTrials.gov/show/NCT00552344 |
| Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Remission in Patients With Crohn's Disease | Completed | Crohn Disease | Biological: certolizumab pegol (CDP870, CZP)|Other: Placebo | UCB Pharma | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment | March 2008 | https://ClinicalTrials.gov/show/NCT00552058 |
| A follow-on Safety Study of CDP870 in Subjects With Crohn's Disease (CD) Who Have Completed a 26-week Double Blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425] | Completed | Crohn's Disease | Biological: Certolizumab Pegol (CDP870) | UCB Pharma SA|UCB Pharma | Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | July 2004 | https://ClinicalTrials.gov/show/NCT00160524 |
| Efficacy (Induction of Response/Remission) and Safety Study in Patients With Moderate to Severe Crohn's Disease | Completed | Crohn Disease | Drug: Sargramostim (Leukine)|Drug: Placebo | Genzyme, a Sanofi Company|Sanofi | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment | September 2004 | https://ClinicalTrials.gov/show/NCT00206674 |
| The Safety And Efficacy Of Maintenance Therapy With CP-690,550 | Completed | Crohn's Disease | Drug: Placebo|Drug: CP-690,550 | Pfizer | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment | March 2012 | https://ClinicalTrials.gov/show/NCT01393899 |
| A follow-on Safety Study in Subjects With Crohn's Disease Who Have Previously Been Withdrawn From the Double-blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425] Due to an Exacerbation of Crohn's Disease | Completed | Crohn's Disease | Biological: Certolizumab Pegol (CDP870) | UCB Pharma SA|UCB Pharma | Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | February 2004 | https://ClinicalTrials.gov/show/NCT00160706 |
| A Open-Label Study Of CP-690,550 As Long-Term Therapy (48 Weeks) In Subjects With Crohn's Disease | Completed | Crohn's Disease | Drug: CP-690,550 | Pfizer | Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | April 2012 | https://ClinicalTrials.gov/show/NCT01470599 |
| Extension Study of MT-1303 in Subjects With Crohn's Disease | Completed | Crohn's Disease | Drug: MT-1303 | Mitsubishi Tanabe Pharma Corporation | Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | August 2015 | https://ClinicalTrials.gov/show/NCT02389790 |
| Safety and Efficacy of MT-1303 in Subjects With Moderate to Severe Active Crohn's Disease | Completed | Crohn's Disease | Drug: MT-1303|Drug: Placebo | Mitsubishi Tanabe Pharma Corporation | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment | March 2015 | https://ClinicalTrials.gov/show/NCT02378688 |
| Efficacy and Safety of Vedolizumab Subcutaneously (SC) as Maintenance Therapy in Ulcerative Colitis | Completed | Colitis, Ulcerative | Drug: Vedolizumab IV 300 mg|Drug: Placebo IV|Drug: Vedolizumab SC 108 mg|Drug: Placebo SC | Takeda | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment | January 8, 2016 | https://ClinicalTrials.gov/show/NCT02611830 |
| Mesalamine 2 g Sachet for the Maintenance of Clinical and Endoscopic Remission in Ulcerative Colitis (UC) | Completed | Ulcerative Colitis | Drug: Mesalamine|Drug: Placebo | Ferring Pharmaceuticals | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment | February 2016 | https://ClinicalTrials.gov/show/NCT02522780 |
| Mesalamine 4 g Sachet for the Induction of Remission in Active, Mild to Moderate Ulcerative Colitis (UC) | Completed | Ulcerative Colitis | Drug: Mesalamine|Drug: Placebo | Ferring Pharmaceuticals | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment | October 2015 | https://ClinicalTrials.gov/show/NCT02522767 |
| Safety and Efficacy of Etrasimod (APD334) in Patients With Ulcerative Colitis | Completed | Ulcerative Colitis | Drug: Etrasimod|Drug: Placebo | Arena Pharmaceuticals | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment | July 2015 | https://ClinicalTrials.gov/show/NCT02447302 |
| A Study of Safety and Effectiveness of JNJ-54781532 in Patients With Moderately to Severely Active Ulcerative Colitis | Completed | Colitis, Ulcerative | Drug: Placebo|Drug: JNJ-54781532 25 mg once daily|Drug: JNJ-54781532 75 mg once daily|Drug: JNJ-54781532 150 mg once daily|Drug: JNJ-54781532 75 mg twice daily | Janssen Research & Development, LLC | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment | November 2013 | https://ClinicalTrials.gov/show/NCT01959282 |
| Phase 2a Study to Evaluate the Safety/Tolerability and Efficacy of TOP1288 200 mg Rectal Solution Once Daily for 4 Weeks in Ulcerative Colitis | Completed | Ulcerative Colitis | Drug: TOP1288|Drug: Placebo (for TOP1288) | Topivert Pharma Ltd | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment | September 2016 | https://ClinicalTrials.gov/show/NCT02888379 |
| A Study Evaluating The Efficacy And Safety Of CP-690,550 In Patients With Moderate To Severe Ulcerative Colitis | Completed | Ulcerative Colitis | Drug: tofacitinib|Drug: Placebo | Pfizer | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment | April 2012 | https://ClinicalTrials.gov/show/NCT01465763 |
| A Study To Evaluate Both The Efficacy and Safety Profile of CP-690,550 In Patients With Moderately to Severely Active Ulcerative Colitis | Completed | Ulcerative Colitis | Drug: tofacitinib|Drug: Placebo | Pfizer | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment | June 2012 | https://ClinicalTrials.gov/show/NCT01458951 |
| Randomized Placebo Controlled Trial of Budesonide Multi-Matrix System (MMX®) 9 mg in Patients With Ulcerative Colitis Currently on a 5-Aminosalicylic Acid (5-ASA). | Completed | Ulcerative Colitis | Drug: Budesonide|Drug: Placebo|Procedure: Procedure/Surgery: Blood sampling, endoscopy | Valeant Pharmaceuticals International, Inc. | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment | February 2012 | https://ClinicalTrials.gov/show/NCT01532648 |
| Efficacy and Safety of Asacol™ 4.8 g/Day (800 mg Tablets) for the Treatment of Active Ulcerative Colitis | Completed | Ulcerative Colitis | Drug: Mesalamin | Tillotts Pharma AG | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment | November 2009 | https://ClinicalTrials.gov/show/NCT01059344 |
| A Study of MDX-1100 in Subjects With Active Ulcerative Colitis | Completed | Ulcerative Colitis | Biological: sterile saline for injection|Biological: MDX-1100 | Bristol-Myers Squibb | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment | April 2008 | https://ClinicalTrials.gov/show/NCT00656890 |
| An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis | Completed | Colitis, Ulcerative | Biological: Placebo|Biological: Golimumab 50 mg|Biological: Golimumab 100 mg|Biological: Golimumab 200 mg | Janssen Research & Development, LLC|Merck Sharp & Dohme Corp. | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment | September 2007 | https://ClinicalTrials.gov/show/NCT00488631 |
| (CB-01-02/02) Randomized Placebo Controlled Trial of Budesonide-multi-matrix System (MMX™) 6 mg and 9 mg in Patients With Ulcerative Colitis | Completed | Ulcerative Colitis | Procedure: Blood sampling, endoscopy|Drug: Budesonide MMX® 6 mg|Drug: Budesonide MMX® 9 mg|Drug: Entocort EC® 3 mg|Drug: Placebo | Valeant Pharmaceuticals International, Inc.|Cosmo Technologies Ltd | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment | June 2008 | https://ClinicalTrials.gov/show/NCT00679380 |
| An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis | Completed | Colitis, Ulcerative | Biological: Placebo|Biological: Golimumab 100 mg|Biological: Golimumab 200 mg|Biological: Golimumab 400 mg|Biological: Golimumab 50 mg | Janssen Research & Development, LLC|Merck Sharp & Dohme Corp. | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment | August 2007 | https://ClinicalTrials.gov/show/NCT00487539 |
| Basiliximab in Moderate to Severe Ulcerative Colitis | Completed | Ulcerative Colitis | Drug: Basiliximab | Cerimon Pharmaceuticals | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment | January 2007 | https://ClinicalTrials.gov/show/NCT00430898 |
| A Study to Evaluate the Accuracy of a Subset of the Length-109 Probe Set Panel (a Genetic Test) in Predicting Response to Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis | Completed | Colitis, Ulcerative | Biological: Golimumab | Janssen Research & Development, LLC | Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | December 2013 | https://ClinicalTrials.gov/show/NCT01988961 |
| A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects With Crohn's Disease Who Completed the Studies M14-431 or M14-433 | Enrolling by invitation | Crohn's Disease | Drug: Upadacitinib|Drug: Placebo for Upadacitinib | AbbVie | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment | March 29, 2018 | https://ClinicalTrials.gov/show/NCT03345823 |
| Filgotinib in Long-Term Extension Study of Adults With Crohn's Disease | Enrolling by invitation | Crohn's Disease | Drug: Filgotinib|Drug: Placebo | Gilead Sciences|Galapagos NV | Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment | March 17, 2017 | https://ClinicalTrials.gov/show/NCT02914600 |
| Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis | Enrolling by invitation | Ulcerative Colitis | Drug: Filgotinib|Drug: Placebo | Gilead Sciences|Galapagos NV | Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment | February 23, 2017 | https://ClinicalTrials.gov/show/NCT02914535 |
| A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Subjects With Ulcerative Colitis (UC) | Enrolling by invitation | Ulcerative Colitis (UC) | Drug: Upadacitinib (ABT-494) | AbbVie | Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | January 31, 2017 | https://ClinicalTrials.gov/show/NCT03006068 |
| An Extension Study to Evaluate the Long-Term Safety and Tolerability of UTTR1147A in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease | Not yet recruiting | Ulcerative Colitis|Crohn's Disease | Drug: UTTR1147A | Genentech, Inc. | Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | January 25, 2019 | https://ClinicalTrials.gov/show/NCT03650413 |
| A Study of Efficacy and Safety of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis | Not yet recruiting | Colitis, Ulcerative | Drug: Guselkumab Dose 1|Drug: Guselkumab Dose 2|Drug: Golimumab Dose 1|Drug: Golimumab Dose 2|Drug: Placebo | Janssen Research & Development, LLC | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment | November 9, 2018 | https://ClinicalTrials.gov/show/NCT03662542 |
| A Study of Tofacitinib in Patients With Ulcerative Colitis in Stable Remission | Recruiting | Ulcerative Colitis | Drug: CP-690,500 5 mg|Drug: CP-690,550 10 mg | Pfizer | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment | November 16, 2017 | https://ClinicalTrials.gov/show/NCT03281304 |
| A Study of Mirikizumab (LY3074828) in Participants With Active Crohn's Disease | Recruiting | Crohn's Disease | Drug: Mirikizumab|Drug: Placebo | Eli Lilly and Company | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment | December 14, 2016 | https://ClinicalTrials.gov/show/NCT02891226 |
| The Efficacy of Cobitolimod in Patients With Moderate to Severe Active Ulcerative Colitis | Recruiting | Ulcerative Colitis | Drug: cobitolimod|Drug: Placebo | InDex Pharmaceuticals | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment | June 21, 2017 | https://ClinicalTrials.gov/show/NCT03178669 |
| An Investigational Study of Experimental Medication BMS-986165 in Patients With Moderate to Severe Crohn's Disease | Recruiting | Granulomatous Colitis|Crohn's Disease|Crohn's Enteritis|Granulomatous Enteritis | Drug: BMS-986165|Other: Placebo | Bristol-Myers Squibb | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment | June 25, 2018 | https://ClinicalTrials.gov/show/NCT03599622 |
| A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | Recruiting | Crohn's Disease | Drug: Guselkumab Dose 1|Drug: Guselkumab Dose 2|Drug: Guselkumab Dose 3|Drug: Guselkumab Dose 4|Drug: Guselkumab Dose 5|Drug: Guselkumab|Drug: Ustekinumab|Drug: Placebo | Janssen Research & Development, LLC | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment | April 13, 2018 | https://ClinicalTrials.gov/show/NCT03466411 |
| A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease | Recruiting | Crohn Disease | Drug: Ozanimod|Other: Placebo | Celgene | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment | June 27, 2018 | https://ClinicalTrials.gov/show/NCT03464097 |
| Induction Study #2 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease | Recruiting | Crohn Disease | Drug: Ozanimod|Other: Placebo | Celgene | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment | March 7, 2018 | https://ClinicalTrials.gov/show/NCT03440385 |
| Induction Study #1 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease | Recruiting | Crohn Disease | Drug: Ozanimod|Other: Placebo | Celgene | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment | February 27, 2018 | https://ClinicalTrials.gov/show/NCT03440372 |
| Study To Evaluate The Efficacy And Safety Of Oral PF-06651600 And PF‑06700841 In Subjects With Moderate To Severe Crohn's Disease | Recruiting | Crohn's Disease | Drug: Placebo PF-06651600|Drug: Placebo PF-06700841|Drug: PF-06651600|Drug: PF-06700841 | Pfizer | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment | February 2, 2018 | https://ClinicalTrials.gov/show/NCT03395184 |
| A Study of the Efficacy and Safety of Upadacitnib (ABT-494) in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional Therapies But Have Not Failed Biologic Therapy | Recruiting | Crohn's Disease | Drug: Upadacitinib|Drug: Placebo for Upadacitinib | AbbVie | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment | December 7, 2017 | https://ClinicalTrials.gov/show/NCT03345849 |
| A Six Week Efficacy, Safety and Tolerability Study of V565 in Crohn's Disease | Recruiting | Crohn's Disease | Drug: V565|Drug: Placebo | VHsquared Ltd. | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment | December 2016 | https://ClinicalTrials.gov/show/NCT02976129 |
| Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's Disease | Recruiting | Crohn's Disease | Drug: Filgotinib|Drug: Placebo to match filgotinib | Gilead Sciences|Galapagos NV | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment | October 2016 | https://ClinicalTrials.gov/show/NCT02914561 |
| Safety and Efficacy Study of JNJ-64304500 in Participants With Moderately to Severely Active Crohn's Disease | Recruiting | Crohn Disease | Drug: JNJ-64304500|Drug: Placebo|Drug: Ustekinumab | Janssen Research & Development, LLC | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment | August 25, 2016 | https://ClinicalTrials.gov/show/NCT02877134 |
| A Study of the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Crohn's Disease | Recruiting | Crohn's Disease | Drug: placebo for risankizumab|Drug: risankizumab IV|Drug: risankizumab SC | AbbVie | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment | May 10, 2017 | https://ClinicalTrials.gov/show/NCT03105128 |
| A Study of the Efficacy and Safety of Risankizumab in Subjects With Crohn's Disease Who Responded to Induction Treatment in M16-006 or M15-991; or Completed M15-989 | Recruiting | Crohn's Disease | Drug: placebo for risankizumab SC|Drug: risankizumab IV|Drug: placebo for risankizumab IV|Drug: risankizumab SC | AbbVie | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment | April 9, 2018 | https://ClinicalTrials.gov/show/NCT03105102 |
| Open-Label Extension and Safety Study for Patients With Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144 | Recruiting | Crohn Disease | Drug: etrolizumab | Hoffmann-La Roche | Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | June 8, 2015 | https://ClinicalTrials.gov/show/NCT02403323 |
| A Study to Assess Whether Etrolizumab is a Safe and Effective Treatment for Participants With Moderately to Severely Active Crohn's Disease (CD) | Recruiting | Crohn Disease | Drug: Etrolizumab|Drug: Placebo | Hoffmann-La Roche | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment | March 20, 2015 | https://ClinicalTrials.gov/show/NCT02394028 |
| Efficacy and Safety of Filgotinib in the Treatment of Small Bowel Crohn's Disease (SBCD) | Recruiting | Small Bowel Crohn's Disease | Drug: Filgotinib|Drug: Placebo to match filgotinib | Gilead Sciences|Galapagos NV | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment | April 11, 2017 | https://ClinicalTrials.gov/show/NCT03046056 |
| A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy | Recruiting | Crohn's Disease | Other: Matching placebo for upadacitinib|Drug: upadacitinib | AbbVie | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment | November 29, 2017 | https://ClinicalTrials.gov/show/NCT03345836 |
| A Study to Assess the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment | Recruiting | Crohn's Disease | Drug: placebo for risankizumab IV|Drug: risankizumab SC|Drug: risankizumab IV | AbbVie | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment | January 3, 2018 | https://ClinicalTrials.gov/show/NCT03104413 |
| A Safety Extension Study of SHP647 in Subjects With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA) | Recruiting | Crohn's Disease|Ulcerative Colitis | Drug: 25 mg SHP647|Drug: 75 mg SHP647 | Shire | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment | February 27, 2018 | https://ClinicalTrials.gov/show/NCT03283085 |
| Vedolizumab Subcutaneous Long-Term Open-Label Extension Study | Recruiting | Colitis, Ulcerative|Crohn Disease | Drug: Vedolizumab SC | Takeda | Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | April 15, 2016 | https://ClinicalTrials.gov/show/NCT02620046 |
| A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of UTTR1147A Compared With Placebo and With Vedolizumab in Participants With Moderate to Severe Ulcerative Colitis (UC) | Recruiting | Ulcerative Colitis | Drug: UTTR1147A|Drug: UTTR1147A Placebo|Drug: Vedolizumab|Drug: Vedolizumab Placebo | Genentech, Inc. | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment | October 26, 2018 | https://ClinicalTrials.gov/show/NCT03558152 |
| An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1) | Recruiting | Ulcerative Colitis | Drug: Mirikizumab|Drug: Placebo | Eli Lilly and Company | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment | June 18, 2018 | https://ClinicalTrials.gov/show/NCT03518086 |
| A Study to Assess the Efficacy and Safety of Risankizumab in Subjects With Ulcerative Colitis Who Responded to Induction Treatment in M16-067 or M16-065 | Recruiting | Ulcerative Colitis (UC) | Drug: risankizumab|Drug: placebo for risankizumab | AbbVie | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment | August 28, 2018 | https://ClinicalTrials.gov/show/NCT03398135 |
| An Efficacy and Safety Study of SHP647 as Maintenance Therapy in Participants With Moderate to Severe Ulcerative Colitis | Recruiting | Ulcerative Colitis | Drug: SHP647|Other: Placebo | Shire | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment | April 4, 2018 | https://ClinicalTrials.gov/show/NCT03290781 |
| A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 302) | Recruiting | Ulcerative Colitis | Drug: SHP647|Drug: Placebo | Shire | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment | October 31, 2017 | https://ClinicalTrials.gov/show/NCT03259308 |
| Study to Evaluate the Testicular Safety of Filgotinib in Adult Males With Moderately to Severely Active Ulcerative Colitis | Recruiting | Ulcerative Colitis | Drug: Filgotinib|Drug: Placebo|Drug: Standard of Care | Gilead Sciences|Galapagos NV | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment | July 11, 2017 | https://ClinicalTrials.gov/show/NCT03201445 |
| Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative Colitis | Recruiting | Ulcerative Colitis | Drug: PF-06651600 or Placebo|Drug: PF-06700841 or Placebo|Drug: PF-06700841|Drug: PF-06651600 | Pfizer | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment | February 3, 2017 | https://ClinicalTrials.gov/show/NCT02958865 |
| Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Ulcerative Colitis | Recruiting | Ulcerative Colitis | Drug: Filgotinib|Drug: Placebo to match filgotinib | Gilead Sciences|Galapagos NV | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment | November 14, 2016 | https://ClinicalTrials.gov/show/NCT02914522 |
| Open-Label Extension of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis | Recruiting | Ulcerative Colitis | Drug: RPC1063 | Celgene | Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | December 2, 2015 | https://ClinicalTrials.gov/show/NCT02531126 |
| A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Ulcerative Colitis | Recruiting | Ulcerative Colitis (UC) | Drug: Upadacitinib (ABT-494)|Drug: Placebo | AbbVie | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment | October 29, 2018 | https://ClinicalTrials.gov/show/NCT03653026 |
| Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative Colitis | Recruiting | Ulcerative Colitis | Drug: RPC1063|Drug: Placebo | Celgene | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment | May 31, 2015 | https://ClinicalTrials.gov/show/NCT02435992 |
| A Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis (UC) | Recruiting | Ulcerative Colitis (UC) | Drug: Placebo|Drug: Updacitinib (ABT-494) | AbbVie | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment | September 26, 2016 | https://ClinicalTrials.gov/show/NCT02819635 |
| A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors (Study #2) | Recruiting | Ulcerative Colitis | Drug: Adalimumab|Other: Adalimumab Placebo|Drug: Etrolizumab|Other: Etrolizumab Placebo | Hoffmann-La Roche | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment | November 14, 2014 | https://ClinicalTrials.gov/show/NCT02171429 |
| A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors (Study #1) | Recruiting | Ulcerative Colitis | Drug: Adalimumab|Other: Adalimumab Placebo|Drug: Etrolizumab|Other: Etrolizumab Placebo | Hoffmann-La Roche | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment | November 4, 2014 | https://ClinicalTrials.gov/show/NCT02163759 |
| A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors | Recruiting | Colitis, Ulcerative | Drug: Etrolizumab|Drug: Placebo | Hoffmann-La Roche | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment | August 12, 2014 | https://ClinicalTrials.gov/show/NCT02165215 |
| Study for Participants With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase II/III Studies | Recruiting | Ulcerative Colitis | Drug: Etrolizumab | Hoffmann-La Roche | Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | September 15, 2014 | https://ClinicalTrials.gov/show/NCT02118584 |
| A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Ulcerative Colitis Who Have Failed Prior Biologic Therapy | Recruiting | Ulcerative Colitis (UC) | Drug: risankizumab IV|Drug: placebo for risankizumab|Drug: risankizumab SC | AbbVie | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment | March 7, 2018 | https://ClinicalTrials.gov/show/NCT03398148 |
| Vedolizumab IV in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD) | Recruiting | Ulcerative Colitis|Crohn's Disease | Drug: Vedolizumab | Takeda | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment | November 8, 2017 | https://ClinicalTrials.gov/show/NCT03138655 |
| Long-term Safety With Vedolizumab Intravenous (IV) in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD) | Recruiting | Ulcerative Colitis|Crohn's Disease | Drug: Vedolizumab | Takeda | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment | July 30, 2018 | https://ClinicalTrials.gov/show/NCT03196427 |
| Open-Label Extension Study of GSK1605786A | Terminated | Crohn's Disease | Drug: GSK1605786A | GlaxoSmithKline | Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | April 1, 2011 | https://ClinicalTrials.gov/show/NCT01318993 |
| A Long-term Active Treatment Study of Mongersen (GED-0301) in Subjects With Crohn's Disease | Terminated | Crohn's Disease | Drug: GED-0301|Other: Placebo | Celgene | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment | July 25, 2016 | https://ClinicalTrials.gov/show/NCT02641392 |
| Efficacy and Safety Study of Mongersen (GED-0301) for the Treatment of Subjects With Active Crohn's Disease | Terminated | Crohn Disease | Drug: GED-0301|Drug: Placebo | Celgene | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment | December 8, 2015 | https://ClinicalTrials.gov/show/NCT02596893 |
| Safety and Efficacy Study of PTG-100 in the Treatment of Moderate to Severe Ulcerative Colitis | Terminated | Ulcerative Colitis | Drug: PTG-100|Drug: Placebo group | Protagonist Therapeutics | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment | December 2016 | https://ClinicalTrials.gov/show/NCT02895100 |
| An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease | Terminated | Crohn's Disease | Drug: GSK1605786A | GlaxoSmithKline | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment | November 11, 2011 | https://ClinicalTrials.gov/show/NCT01536418 |
| GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease | Terminated | Crohn's Disease | Drug: GSK1605786A|Drug: Placebo | GlaxoSmithKline | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment | May 9, 2011 | https://ClinicalTrials.gov/show/NCT01316939 |
| Efficacy (Induction of Response/Remission) and Safety Study in Patients With Moderate to Severe Crohn's Disease | Terminated | Crohn Disease | Drug: Sargramostim (Leukine)|Drug: Placebo | Genzyme, a Sanofi Company|Sanofi | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment | January 2006 | https://ClinicalTrials.gov/show/NCT00295165 |
| Open-label Trial of Leukine in Active Crohn's Disease | Terminated | Crohn Disease | Drug: Sargramostim (Leukine) | Genzyme, a Sanofi Company|Sanofi | Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment | February 2003 | https://ClinicalTrials.gov/show/NCT00206700 |
| Efficacy and Safety Study of GED-0507-34-Levo for Treatment of UC | Terminated | Ulcerative Colitis | Drug: GED-0507-34-Levo 80 mg|Drug: GED-0507-34-Levo 160 mg|Drug: Placebo | PPM Services S.A. | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment | November 28, 2016 | https://ClinicalTrials.gov/show/NCT02808390 |
| Safety and Efficacy of GS-5745 in Adults With Moderately to Severely Active Ulcerative Colitis | Terminated | Ulcerative Colitis | Biological: GS-5745|Biological: Placebo | Gilead Sciences | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment | September 2015 | https://ClinicalTrials.gov/show/NCT02520284 |
| An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis | Terminated | Colitis, Ulcerative | Other: Placebo|Drug: Golimumab 1 mg per kg|Drug: Golimumab 2 mg per kg|Drug: Golimumab 4 mg per kg | Janssen Research & Development, LLC|Merck Sharp & Dohme Corp. | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment | August 2007 | https://ClinicalTrials.gov/show/NCT00488774 |
| A Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis | Terminated | Ulcerative Colitis | Drug: visilizumab | Facet Biotech|PDL BioPharma, Inc. | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment | February 2006 | https://ClinicalTrials.gov/show/NCT00279422 |
| A Placebo-controlled Trial With rFXIII Administered to Subjects With Mild to Moderate Active Ulcerative Colitis | Terminated | Inflammation|Ulcerative Colitis | Drug: catridecacog|Drug: placebo | Novo Nordisk A/S | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment | October 2012 | https://ClinicalTrials.gov/show/NCT01706159 |
| An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative Colitis | Terminated | Ulcerative Colitis | Drug: Visilizumab (Nuvion®; HuM291) | PDL BioPharma, Inc.|Facet Biotech | Time Perspective: Prospective | September 2006 | https://ClinicalTrials.gov/show/NCT00355901 |
| Study of Visilizumab Versus Placebo in Subjects With Intravenous Steroid-refractory Ulcerative Colitis Previously Responsive in a Visilizumab Study | Terminated | Ulcerative Colitis | Drug: visilizumab | Facet Biotech|PDL BioPharma, Inc. | Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment | August 2006 | https://ClinicalTrials.gov/show/NCT00279435 |
| A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease | Withdrawn | Crohn Disease | Drug: GED-0301|Drug: Placebo | Celgene | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment | December 1, 2017 | https://ClinicalTrials.gov/show/NCT02974322 |
